Evidence map›Paper›PMID 42321166›Full record

ArticleNature communications2026

PERK orchestrates an endoplasmic reticulum stress alternative splicing program via CLK1/SRSF1.

Céline Philippe, Shoshana Burke, Arantxa Carrasco-Leon, Andrea Martisova, Pedro Casado, Eleni Maniati, Jimena Castorena, Pantelitsa Protopapa, Alyssa Fronk, Ru-Pin Alicia Chi and 19 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Céline PhilippeBarts Cancer Institute, Queen Mary University of London, London, UK. celine.philippe@univ-rennes.fr.ORCID 0000-0002-8546-3893
Shoshana Burke *Barts Cancer Institute, Queen Mary University of London, London, UK.
Arantxa Carrasco-Leon *Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-4584-443X
Andrea Martisova *Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-0081-0498
Pedro CasadoBarts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-4207-9349
Eleni ManiatiBarts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0001-6993-9890
Jimena CastorenaINSERM U1342, Equipe Leader Fondation ARC 2024, IRSL, St Louis Hospital, University of Paris-Cité, Paris, France.ORCID 0009-0005-8174-6086
Pantelitsa ProtopapaBarts Cancer Institute, Queen Mary University of London, London, UK.
Alyssa FronkEnvisagenics Inc., Queens, NY, USA.
Ru-Pin Alicia ChiReproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Durham, NC, USA.ORCID 0000-0003-2930-9362
Rachel BonifaceINSERM U1242, University of Rennes, Centre de Lutte contre le Cancer Eugène Marquis, Rennes, France.ORCID 0009-0000-3303-8089
Vinothini RajeeveBarts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-6361-4291
Martin DodelDepartment of Biochemistry, University of Oxford, Oxford, UK.
Beatriz GalvãoBarts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-0249-9285
Marc AubryINSERM U1242, University of Rennes, Centre de Lutte contre le Cancer Eugène Marquis, Rennes, France.
Kaliya Svetlinova GeorgievaBarts Cancer Institute, Queen Mary University of London, London, UK.
Doriana Di BellaBarts Cancer Institute, Queen Mary University of London, London, UK.
Brian N PapasIntegrative Bioinformatics, Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Durham, NC, USA.ORCID 0000-0003-4540-1142
Taylor FloydEnvisagenics Inc., Queens, NY, USA.
Kendall AndersonEnvisagenics Inc., Queens, NY, USA.
Martin AkermanEnvisagenics Inc., Queens, NY, USA.
Jun WangBarts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0003-2509-9599
Lovorka StojicBarts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0001-6691-3396
Faraz MardakhehDepartment of Biochemistry, University of Oxford, Oxford, UK.ORCID 0000-0003-3896-0827
Marcos MorganReproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Durham, NC, USA.ORCID 0000-0002-3549-0375
Eric ChevetINSERM U1242, University of Rennes, Centre de Lutte contre le Cancer Eugène Marquis, Rennes, France.ORCID 0000-0001-5855-4522
Christian TouriolINSERM U1037, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.ORCID 0000-0003-1219-4693
Pedro R CutillasBarts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-3426-2274
Kevin Rouault-PierreBarts Cancer Institute, Queen Mary University of London, London, UK. kevin.rouault-pierre@inserm.fr.ORCID 0000-0001-7671-7364

Funding

Role of RNA modifications in spermatogenesis.ZIAES103339 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI MORGAN, MARCOS · 2019 to 2025
$10.8M
Academy of Medical Sciences SBF004\1099Agence Nationale de la Recherche (French National Research Agency) ANR-23-IAHU-0005Cancer Research UK (CRUK) EDDPJT-May23/100019European Hematology Association (EHA) RG109Fondation ARC pour la Recherche sur le Cancer (ARC Foundation for Cancer Research) ARCLEADER2024020007943Intramural NIH HHS ZIA ES103339Kay Kendall Leukaemia Fund (KKLF) KKL1149Lady Tata Memorial Trust 3218
6 · The paper itself

Abstract

The unfolded protein response (UPR) is a critical adaptive program triggered upon cellular stresses that profoundly reshapes the transcriptome and translatome. In the very first minutes of cellular stress, translation blockage, RNA decay and RNA granules formation prompt the synthesis of proteins essential to the stress response. Due to the dynamic nature of these processes, investigating translation upon stress has proven to be challenging; therefore, our understanding of these mechanisms and translatome rewiring upon stress remains limited. Here, we exploit O-Propargyl-puromycin (OPP) labelling of de novo peptides followed by LC-MS/MS to identify de novo proteins translated upon endoplasmic reticulum (ER) stress. Combined with transcriptomic analyses, our approach reveals that ER stress profoundly impacts the synthesis of core splicing factor proteins leading to a significant reshaping of the splicing landscape. We identify a signature of seven splicing events consistently occurring in mammalian cells exposed to ER stress. Using pharmacological, genetic, phosphoproteomic and sequencing approaches, we demonstrate that this specific signature is driven by PERK activation and is dependent on the axis CLK1/SRSF1. Our findings identify PERK/CLK1/SRSF1 -mediated splicing regulation as a new facet of ER stress, defining an ER

Indexed as

Alternative SplicingeIF-2 KinaseEndoplasmic Reticulum StressProtein Serine-Threonine KinasesSerine-Arginine Splicing FactorsAnimalsHeLa CellsHumansProtein-Tyrosine KinasesUnfolded Protein ResponseClk dual-specificity kinaseseIF-2 KinaseProtein Serine-Threonine KinasesProtein-Tyrosine KinasesSerine-Arginine Splicing Factors

Identifiers

PMID42321166
PMCPMC13434015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.